The estimated Net Worth of Barry D Quart is at least $6.02 Milion dollars as of 5 June 2024. Barry Quart owns over 4,373 units of Heron Therapeutics Inc stock worth over $16,965 and over the last 10 years he sold HRTX stock worth over $130,700. In addition, he makes $5,870,480 as Chairman of the Board i Chief Executive Officer at Heron Therapeutics Inc.
Barry has made over 26 trades of the Heron Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 4,373 units of HRTX stock worth $7,915 on 5 June 2024.
The largest trade he's ever made was exercising 100,000 units of Heron Therapeutics Inc stock on 19 March 2018 worth over $720,000. On average, Barry trades about 12,492 units every 93 days since 2014. As of 5 June 2024 he still owns at least 9,373 units of Heron Therapeutics Inc stock.
You can see the complete history of Barry Quart stock trades at the bottom of the page.
Dr. Barry D. Quart Pharm.D. serves as Chairman of the Board, Chief Executive Officer of the Company. Dr. Quart was appointed Chief Executive Officer in 2013 and President and Chief Executive Officer in February 2019. He has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through 2013, and as a director through its acquisition by AstraZeneca PLC in 2012. Previously, he was with Pfizer Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. He joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in 2015. Since 2015, he has served as a director of Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.
As the Chairman of the Board i Chief Executive Officer of Heron Therapeutics Inc, the total compensation of Barry Quart at Heron Therapeutics Inc is $5,870,480. There are no executives at Heron Therapeutics Inc getting paid more.
Barry Quart is 63, he's been the Chairman of the Board i Chief Executive Officer of Heron Therapeutics Inc since 2020. There are 1 older and 20 younger executives at Heron Therapeutics Inc. The oldest executive at Heron Therapeutics Inc is Dr. Barry D. Quart, 64, who is the Chairman & CEO.
Barry's mailing address filed with the SEC is C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE 2 CHURCH STREET, HAMILTON, D0, HM 11.
Over the last 11 years, insiders at Heron Therapeutics Inc have traded over $96,663,574 worth of Heron Therapeutics Inc stock and bought 6,549,746 units worth $56,275,132 . The most active insiders traders include Kevin Ctang Capital Managem..., Adam Morgan oraz Craig A Collard. On average, Heron Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $176,989. The most recent stock trade was executed by Craig A Collard on 19 July 2024, trading 13,797 units of HRTX stock currently worth $24,973.
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
Heron Therapeutics Inc executives and other stock owners filed with the SEC include: